middle.news
Paradigm Biopharma Advances Phase 3 Trial with FDA Nod and $16M Raise
6:46pm on Sunday 1st of June, 2025 AEST
•
Biotechnology
Read Story
Paradigm Biopharma Advances Phase 3 Trial with FDA Nod and $16M Raise
6:46pm on Sunday 1st of June, 2025 AEST
Key Points
FDA clears Paradigm's revised phase 3 trial protocol with no queries
Successful $16 million capital raise at a 2.9% premium to fund trial activities
Received $6.3 million R&D tax incentive rebate bolstering cash reserves
Australian centralised ethics submission underway, approval expected Q1 2025
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
PAR
OPEN ARTICLE